• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.

作者信息

Spósito A C, Caramelli B, Serrano C V, Mansur A P, Ramires J A

机构信息

Heart Institute (InCor), University of São Paulo Medical School, Brazil.

出版信息

Am J Cardiol. 1999 Jan 1;83(1):98-100, A8. doi: 10.1016/s0002-9149(98)00787-5.

DOI:10.1016/s0002-9149(98)00787-5
PMID:10073791
Abstract

Niacin treatment (alone) was compared with etofibrate and niacin combination to treat patients with high-density lipoprotein <35 mg/dl and without hypertriglyceridemia. The niacin and etofibrate combination proved to be safe and increased high-density lipoprotein cholesterol levels to 48%, which was 3 times higher than that obtained with niacin alone.

摘要

相似文献

1
Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl.
Am J Cardiol. 1999 Jan 1;83(1):98-100, A8. doi: 10.1016/s0002-9149(98)00787-5.
2
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
Braz J Med Biol Res. 2001 Feb;34(2):177-82. doi: 10.1590/s0100-879x2001000200004.
3
Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.益多酯对冠心病患者乳糜微粒样乳剂代谢的影响。
Atherosclerosis. 2001 Feb 1;154(2):455-61. doi: 10.1016/s0021-9150(00)00491-3.
4
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].[单独使用缓释烟酸或与阿托伐他汀联合使用对血脂谱改善的疗效及安全性]
Zhonghua Yi Xue Za Zhi. 2006 Sep 12;86(34):2399-403.
5
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.增加高密度脂蛋白胆固醇化合物的疗效与安全性：一项随机对照试验的荟萃分析
J Am Coll Cardiol. 2005 Jan 18;45(2):185-97. doi: 10.1016/j.jacc.2004.10.031.
6
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].安妥明丙二醇酯缓释制剂对IIa型高脂蛋白血症患者的降脂范围及疗效（作者译）
Med Klin. 1979 Dec 21;74(51-52):1953-6.
7
Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease.缓释烟酸疗法对“单纯”高密度脂蛋白胆固醇水平极低且患有冠状动脉疾病的患者有显著益处。
Am J Cardiol. 1992 Apr 15;69(12):1083-5. doi: 10.1016/0002-9149(92)90868-y.
8
Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.烟酸和贝特类药物在高甘油三酯和低高密度脂蛋白胆固醇患者中的应用。
Curr Med Res Opin. 2009 Jun;25(6):1355-63. doi: 10.1185/03007990902910450.
9
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.ARBITER 6-HALTS 试验（动脉生物学用于研究降低胆固醇 6-HDL 和 LDL 治疗策略在动脉粥样硬化中的治疗效果）：最终结果以及药物依从性、剂量和治疗持续时间的影响。
J Am Coll Cardiol. 2010 Jun 15;55(24):2721-6. doi: 10.1016/j.jacc.2010.03.017.
10
Fluvastatin with and without niacin for hypercholesterolemia.氟伐他汀联合或不联合烟酸治疗高胆固醇血症。
Am J Cardiol. 1994 Jul 15;74(2):149-54. doi: 10.1016/0002-9149(94)90088-4.

引用本文的文献

1
Niacin for primary and secondary prevention of cardiovascular events.用于心血管事件一级和二级预防的烟酸
Cochrane Database Syst Rev. 2017 Jun 14;6(6):CD009744. doi: 10.1002/14651858.CD009744.pub2.
2
Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment.低高密度脂蛋白胆固醇：生理背景、临床意义及药物治疗。
Drugs. 2003;63(18):1907-45. doi: 10.2165/00003495-200363180-00003.